drugset / Trial / NCT07257588

The Efficacy of Hyperbaric Oxygen-assisted Treatment for ASUC and Refractory IBD

NCT07257588

Enrolling by invitation 44 enrolled Xijing Hospital of Digestive Diseases
RandomizedParallel-groupOpen-labelTreatment

Summary

The Department of Gastroenterology plans to conduct a randomized controlled study on the efficacy analysis of hyperbaric oxygen-assisted treatment for acute severe ulcerative colitis and refractory inflammatory bowel disease. The research design is a randomized, controlled study. The objective is to compare the clinical remission rate, clinical response rate, endoscopic remission rate, and endoscopic response rate between patients with acute severe ulcerative colitis (ASUC) and refractory inflammatory bowel disease (IBD) treated with hyperbaric oxygen therapy (HBOT) as an adjuvant and those treated with standard treatment regimens. This study aims to provide clear evidence for the use of HBOT as an adjuvant treatment for ASUC and refractory IBD.

Timeline

Start
2024-09-30
Primary completion
2025-12-31
Completion
2025-12-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Background Methylprednisolone Other / unclassified 40 mg Intravenous

Indications